Court Grants Final Approval of $9.5 Million Eagle Pharmaceuticals Securities Settlement
Wed 26th Aug 2026 | Posted by Melissa Wright, on General, News,
The United States District Court for the District of New Jersey has granted final approval to a $9,500,000 all-cash settlement resolving securities fraud claims brought on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (formerly NASDAQ: EGRX) common stock. Glancy Prongay Wolke & Rotter LLP served as Court-appointed Lead Counsel for the certified Settlement Class.
The Honorable Michael A. Hammer, United States Magistrate Judge, entered judgment approving the settlement on August 19, 2026. Carella, Byrne, Cecchi, Brody & Agnello, P.C. served as Liaison Counsel. The action was prosecuted on behalf of Court-appointed lead plaintiff Evans Associates I, LLC and named plaintiffs Nicholas Miller, Liyu Wang, and Joanna Pluta.
Case Snapshot
| Case | Miller v. Eagle Pharmaceuticals, Inc. |
|---|---|
| Court | U.S. District Court for the District of New Jersey |
| Docket No. | 2:23-cv-23011-MAH |
| GPWR’s Role | Court-appointed Lead Counsel |
| Amount Recovered | $9,500,000 (cash) |
| Practice Area | Securities Class Action |
| Summary | Glancy Prongay Wolke & Rotter LLP, as Court-appointed Lead Counsel, recovered $9.5 million for Eagle Pharmaceuticals, Inc. investors who alleged the company overstated revenue from its oncology drug Pemfexy and misrepresented the effectiveness of its internal controls over financial reporting, culminating in an October 2024 announcement that certain financial statements could no longer be relied upon. |
The Settlement Class
The Court certified a Settlement Class consisting of all persons and entities who purchased the publicly traded common stock of Eagle Pharmaceuticals, Inc. between August 9, 2022 and October 1, 2024, both dates inclusive, and who were damaged thereby. Certain persons and entities are excluded from the Settlement Class by definition, including Eagle’s officers and directors during the class period and members of their immediate families. The full class definition and list of exclusions appear in the Court-approved Notice.
The Allegations
The litigation concerned allegedly false and misleading statements by Eagle Pharmaceuticals and two of its executives, Scott Tarriff and Brian Cahill, regarding the company’s sales of its oncology drug Pemfexy and the effectiveness of Eagle’s internal controls over financial reporting.
Plaintiffs alleged that Eagle had experienced slower-than-anticipated product pull-through from a wholesale customer and that, as a result, the company overstated the revenue it reported from Pemfexy sales beginning with the second quarter of 2022. On October 2, 2024, Eagle filed a Form 8-K announcing that its financial statements dating back to the quarter ended June 30, 2022 should no longer be relied upon and would need to be restated. Trading in Eagle common stock was suspended on Nasdaq on October 3, 2024, and the stock thereafter traded on the OTC Expert Market.
Defendants denied and continue to deny all allegations of wrongdoing or liability. The settlement is not an admission of liability by any defendant, and the Court’s judgment makes no finding of wrongdoing.
How to File a Claim
Settlement Class Members who wish to receive a payment from the Net Settlement Fund must submit a valid Claim Form, postmarked or submitted online no later than October 16, 2026.
Claim Forms and the full Notice are available at www.EaglePharmaSecuritiesSettlement.com, or from the Claims Administrator:
Eagle Pharmaceuticals Securities Litigation
c/o Epiq
P.O. Box 4790
Portland, OR 97208-4790
1-877-313-8718
Settlement Class Members who do not submit a timely, valid Claim Form will not share in the distribution but will remain bound by the Court’s judgment and the releases it provides.
Frequently Asked Questions
Who is eligible to recover from the Eagle Pharmaceuticals settlement?
Investors who purchased Eagle Pharmaceuticals, Inc. publicly traded common stock between August 9, 2022 and October 1, 2024, inclusive, and who were damaged as a result, are Settlement Class Members, subject to the exclusions in the Court-approved Notice.
What is the deadline to file a claim?
Claim Forms must be postmarked or submitted online no later than October 16, 2026.
How much was the Eagle Pharmaceuticals securities settlement?
The settlement is $9,500,000 in cash, obtained by Glancy Prongay Wolke & Rotter LLP as Court-appointed Lead Counsel and approved by the U.S. District Court for the District of New Jersey on August 19, 2026.
What happens if I do nothing?
Settlement Class Members who do not submit a timely, valid Claim Form receive no payment but remain bound by the Court’s judgment and the releases it provides.
About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP is a national law firm representing investors and consumers in complex litigation, with a practice concentrated in securities class actions and shareholder litigation. The firm is headquartered in Los Angeles and has recovered more than $1 billion for investors.
Contact
Garth A. Spencer, Esq.
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
(310) 201-9150 | settlements@glancylaw.com
The case is Miller v. Eagle Pharmaceuticals, Inc., No. 2:23-cv-23011-MAH (D.N.J.).